Xtant Medical (NYSEAMERICAN:XTNT) Announces Earnings Results

Xtant Medical (NYSEAMERICAN:XTNT) announced its quarterly earnings results on Tuesday. The medical device company reported $0.03 earnings per share (EPS) for the quarter, reports. The company had revenue of $32.36 million during the quarter, compared to the consensus estimate of $30.75 million. Xtant Medical had a return on equity of 3.77% and a net margin of 1.32%.

Here are the key takeaways from Xtant Medical’s conference call:

• Q4 revenue was $32.4 million (+3% YoY) and full‑year 2025 revenue was $133.9 million (+14% YoY), with adjusted EBITDA of $16.3 million and $5.0 million net income, reflecting sustained operational discipline and positive cash flow.
• Management completed the sale of Coflex and international Paradigm Spine assets to Companion Spine for about $21.4 million in early December and used proceeds to reduce debt and sharpen focus on core high‑margin biologics.
• 2026 guidance of $95M–$99M excludes the divested businesses and one‑time license income, implying a material year‑over‑year revenue decline even as the company expects to preserve positive free cash flow.
• Company has doubled regional sales reps, plans to expand national accounts, and launched new products (nanOss Strata, CollagenX) — management expects these investments and a full biologics portfolio to accelerate organic biologics growth as reps ramp.
• Hardware revenue is expected to decline steadily (approaching high‑teens% in 2026) and inventory/obsolescence charges remain a headwind; management forecasts gross margin around the low‑60s% for 2026.

Xtant Medical Stock Performance

Shares of Xtant Medical stock traded up $0.00 during trading hours on Wednesday, hitting $0.56. 23,093 shares of the company were exchanged, compared to its average volume of 154,378. The company has a current ratio of 2.21, a quick ratio of 1.06 and a debt-to-equity ratio of 0.35. The business has a 50-day moving average of $0.60 and a 200-day moving average of $0.67. Xtant Medical has a 1 year low of $0.34 and a 1 year high of $0.95. The stock has a market capitalization of $78.58 million, a price-to-earnings ratio of 56.19 and a beta of -0.30.

Hedge Funds Weigh In On Xtant Medical

Large investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new stake in shares of Xtant Medical in the second quarter valued at approximately $26,000. Wiregrass Investment Management LLC acquired a new stake in Xtant Medical in the fourth quarter valued at $81,000. Mink Brook Asset Management LLC boosted its position in shares of Xtant Medical by 125.8% during the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after purchasing an additional 60,997 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Xtant Medical by 28.8% during the 4th quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock worth $721,000 after purchasing an additional 205,945 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Xtant Medical by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after purchasing an additional 104,159 shares in the last quarter. Hedge funds and other institutional investors own 69.33% of the company’s stock.

Trending Headlines about Xtant Medical

Here are the key news stories impacting Xtant Medical this week:

• Positive Sentiment: Q4 beat on EPS and revenue; full‑year 2025 revenue growth and positive operating metrics (net income, adjusted EBITDA, operating cash flow) — supports fundamentals and reduces near‑term cash risk. PR News Release
• Positive Sentiment: Analyst support: BTIG kept a Buy rating while lowering its price target from $1.50 to $1.00 — still implying significant upside from current levels, which can underpin investor interest. Benzinga Item
• Neutral Sentiment: Earnings call and full transcripts are available (InsiderMonkey, Seeking Alpha, MarketBeat) for investors who want detailed management commentary on product trends, margin drivers and the divestiture impact. InsiderMonkey Transcript
• Neutral Sentiment: Additional coverage/highlights published (Yahoo Finance summary) that restates the beat and revenue strength — useful for broader market visibility but not new substantive data. Yahoo Finance
• Negative Sentiment: Management’s 2026 revenue outlook of $95M–$99M (impacted by the Companion Spine divestiture and the winding down of Q‑code license revenue) is materially lower than implied growth expectations, and the weak outlook drove a near‑term share decline. MSN Outlook Article
• Negative Sentiment: Market reaction: coverage noted shares fell nearly 5% as the conservative 2026 guide overshadowed the Q4 beat — signals investor concern about near‑term revenue visibility and organic growth cadence. MSN Market Reaction

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on XTNT shares. Craig Hallum reissued a “buy” rating on shares of Xtant Medical in a report on Wednesday, March 18th. BTIG Research lowered their target price on shares of Xtant Medical from $1.50 to $1.00 and set a “buy” rating on the stock in a research report on Tuesday. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $1.00.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.